BCHE and Alzheimer disease: According to the BChE selectivity and antioxidant properties as well as drug-like properties, which points toward BBB permeability, and favorable toxicological profile the mitochondriotropic antioxidant AntiOxBEN1 is considered a valid candidate for the development of a dual acting drugs useful for AD therapy, which should be validated in animal models relevant for the disease.